NPT520-34 Phase 1 Clinical Trial To Begin For ALS Treatment
With May being ALS Awareness Month comes the news of the beginning of testing an investigational treatment for the disease in healthy volunteer participants. NPT520-34 is an investigational small molecule that has shown to reduce levels of brain inflammation markers and central nervous system proteins of animal models of ALS, Alzheimer’s Disease and Parkinson’s disease. …